Neutrophil-lymphocyte ratio as a predictive marker for progression free survival in patients with advanced cutaneous squamous cell carcinoma prior to Cemiplimab treatment – a real-life setting
Saved in:
| Main Authors: | I. Ciobotariu, A. Di Stefani, A. Paradisi, L. Di Nardo, K. Peris |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-01-01
|
| Series: | EJC Skin Cancer |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2772611824002246 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cemiplimab Immunotherapy in the Treatment of Cutaneous Squamous Cell Carcinoma
by: Z. Kozéki, et al.
Published: (2024-01-01) -
Neutrophil-to-lymphocyte ratio: A surrogate marker for prognosis of oral squamous cell carcinoma
by: R Mahalakshmi, et al.
Published: (2018-01-01) -
Efficacy and safety of cemiplimab in cutaneous squamous cell carcinoma on chronic wounds: A French retrospective study
by: M. Antoszczak, et al.
Published: (2024-12-01) -
The neutrophil-to-lymphocyte ratio in aging and immunosenescence
by: Roberto Paganelli, et al.
Published: (2025-06-01) -
Cemiplimab-Induced Vogt-Koyanagi-Harada-Like Syndrome in a Patient With Cutaneous Squamous Cell Carcinoma of the Lower Back
by: Shapoo Nidha MD, et al.
Published: (2025-06-01)